EC Number |
Substrates |
Products |
Reversibility |
---|
1.14.14.94 | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate + [reduced NADPH-hemoprotein reductase] + O2 |
- |
(6Z,8E,10E,14Z)-(5S,12R)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
- |
? |
1.14.14.94 | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate + [reduced NADPH-hemoprotein reductase] + O2 |
inactivation of leukotriene B4, a mediator of inflammation |
(6Z,8E,10E,14Z)-(5S,12R)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
- |
? |
1.14.14.94 | (6Z,8E,10E,14Z)-(5S,12R)-5,12-dihydroxyicosa-6,8,10,14-tetraenoate + [reduced NADPH-hemoprotein reductase] + O2 |
LTB4 inactivation, in vivo inhibition of CYP4F18 results in a marked increase in calcium flux and a 220% increases in the chemotactic response of mouse polymorphonuclear leukocytes to LTB4 |
(6Z,8E,10E,14Z)-(5S,12R)-5,12,20-trihydroxyicosa-6,8,10,14-tetraenoate + [oxidized NADPH-hemoprotein reductase] + H2O |
- |
? |
1.14.14.94 | (E,Z,Z,Z)-8-hydroxy-5,9,11,14-eicosatetraenoic acid + [reduced NADPH-hemoprotein reductase] + O2 |
CYP4F2 |
? |
- |
? |
1.14.14.94 | (Z12(13))-epoxyoctadec-(Z9)-enoic acid + [reduced NADPH-hemoprotein reductase] + O2 |
- |
? |
- |
? |
1.14.14.94 | (Z12(13))-epoxyoctadec-Z9-enoic acid + [reduced NADPH-hemoprotein reductase] + O2 |
- |
? |
- |
? |
1.14.14.94 | (Z9(10))-epoxyoctadec-(Z12)-enoic acid + [reduced NADPH-hemoprotein reductase] + O2 |
- |
? |
- |
? |
1.14.14.94 | (Z9(10))-epoxyoctadec-Z12-enoic acid + [reduced NADPH-hemoprotein reductase] + O2 |
- |
? |
- |
? |
1.14.14.94 | (Z9(10))-epoxyoctadecanoic acid + NADPH + O2 |
omega-hydroxylation activity and weak (omega-1)-hydroxylation activity |
? |
- |
? |
1.14.14.94 | 12-hydroxy-5,8,10,14-eicosatetraenoic acid + [reduced NADPH-hemoprotein reductase] + O2 |
- |
? |
- |
? |